US Stock MarketDetailed Quotes
MDGL Madrigal Pharmaceuticals
- 350.700
- -4.150-1.17%
Close Nov 8 16:00 ET
- 349.000
- -1.700-0.48%
Post 20:01 ET
7.65BMarket Cap-14011P/E (TTM)
357.045High343.000Low454.43KVolume356.710Open354.850Pre Close158.46MTurnover4.23%Turnover RatioLossP/E (Static)21.81MShares368.29052wk High9.84P/B3.76BFloat Cap135.15052wk Low--Dividend TTM10.73MShs Float415.800Historical High--Div YieldTTM3.96%Amplitude6.600Historical Low348.695Avg Price1Lot Size
Madrigal Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 21.12%-66.98M | -79.19%-134.95M | -77.43%-149.16M | -44.19%-324.23M | -36.60%-79.93M | -43.76%-84.92M | -31.29%-75.31M | -68.43%-84.07M | -22.26%-224.86M | -21.78%-58.52M |
| Net income from continuing operations | -8.33%-106.96M | -77.12%-151.97M | -91.87%-147.54M | -26.50%-373.63M | -30.60%-112.19M | -21.61%-98.74M | -21.31%-85.8M | -33.69%-76.9M | -22.12%-295.35M | -33.08%-85.91M |
| Depreciation and amortization | 120.74%298K | 111.90%267K | 35.48%168K | 12.85%527K | 10.08%142K | 11.57%135K | 14.55%126K | 15.89%124K | 15.31%467K | 21.70%129K |
| Other non cash items | -96.74%22K | -14.80%472K | 51.27%655K | 202.89%2.41M | 146.08%753K | 115.34%674K | --554K | --433K | --797K | --306K |
| Change In working capital | 6,100.00%21.76M | -597.94%-8.12M | -17.72%-22.34M | -108.71%-3.28M | -12.50%16.51M | -97.41%351K | -122.64%-1.16M | -90,471.43%-18.98M | 22.68%37.6M | 88.05%18.87M |
| -Change in receivables | ---23.56M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Change in inventory | ---1.64M | ---6.22M | ---854K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| -Change in prepaid assets | -10,096.61%-5.9M | 32.26%-928K | -1,481.35%-10.89M | 55.85%-555K | -102.42%-32K | 105.18%59K | 12.35%-1.37M | 551.24%788K | -286.77%-1.26M | -46.44%1.33M |
| -Change in payables and accrued expense | 18,005.14%52.87M | 2,763.77%5.93M | 46.36%-10.6M | -107.00%-2.72M | -5.71%16.55M | -98.02%292K | -96.91%207K | -19,666.00%-19.77M | 25.46%38.86M | 132.06%17.55M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 21.12%-66.98M | -79.19%-134.95M | -77.43%-149.16M | -44.19%-324.23M | -36.60%-79.93M | -43.76%-84.92M | -31.29%-75.31M | -68.43%-84.07M | -22.26%-224.86M | -21.78%-58.52M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -503.18%-202.39M | -3,171.65%-122.1M | 152.47%98.05M | -343.13%-502.52M | -645.47%-362.12M | -22.93%50.2M | -119.40%-3.73M | -434.13%-186.86M | 4,188.74%206.69M | 324.39%66.39M |
| Net PPE purchase and sale | -129.79%-779K | -89.86%-131K | -920.00%-357K | -581.57%-1.48M | -3,472.41%-1.04M | -927.27%-339K | 33.01%-69K | 32.69%-35K | -3.83%-217K | 74.34%-29K |
| Net intangibles purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | -498.93%-201.61M | -3,093.20%-116.97M | 152.67%98.41M | -342.16%-501.04M | -643.67%-361.09M | -22.45%50.54M | -118.94%-3.66M | -433.75%-186.83M | 4,369.56%206.9M | 321.53%66.42M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -503.18%-202.39M | -3,171.65%-122.1M | 152.47%98.05M | -343.13%-502.52M | -645.47%-362.12M | -22.93%50.2M | -119.40%-3.73M | -434.13%-186.86M | 4,188.74%206.69M | 324.39%66.39M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -61.89%7.46M | 212.42%134.12M | 988.83%573.71M | 89.86%595.12M | 81.55%479.92M | 19.58M | -12.59%42.93M | 52.69M | 83.05%313.45M | 1,255.37%264.34M |
| Net issuance payments of debt | --0 | --0 | --0 | 30.00%65M | --0 | --15M | -70.00%15M | --35M | --50M | --0 |
| Net common stock issuance | --0 | 295.10%85.95M | --311.56M | 1.88%260.19M | -7.71%235.7M | --2.73M | --21.75M | --0 | 50.04%255.38M | 1,247.09%255.38M |
| Proceeds from stock option exercised by employees | 287.64%7.46M | 670.66%48.17M | 1,364.25%262.15M | 2,918.34%270.29M | 2,627.11%244.21M | --1.93M | --6.25M | --17.9M | 769.42%8.96M | 1,543.12%8.96M |
| Net other financing activities | ---- | ---- | ---- | 59.03%-363K | --0 | ---75K | ---75K | ---213K | ---886K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -61.89%7.46M | 212.42%134.12M | 988.83%573.71M | 89.86%595.12M | 81.55%479.92M | --19.58M | -12.59%42.93M | --52.69M | 83.05%313.45M | 1,255.37%264.34M |
| Net cash flow | ||||||||||
| Beginning cash position | 547.18%499.6M | 449.40%622.52M | -69.86%99.92M | 814.14%331.55M | 4.58%62.06M | 44.91%77.2M | 167.98%113.31M | 814.14%331.55M | -32.84%36.27M | 20.67%59.34M |
| Current changes in cash | -1,629.83%-261.91M | -240.39%-122.92M | 339.46%522.6M | -178.45%-231.63M | -86.09%37.86M | -349.52%-15.14M | -428.59%-36.11M | -3,729.49%-218.24M | 1,764.96%295.28M | 2,209.33%272.21M |
| End cash Position | 283.02%237.68M | 547.18%499.6M | 449.40%622.52M | -69.86%99.92M | -69.86%99.92M | 4.58%62.06M | 44.91%77.2M | 167.98%113.31M | 814.14%331.55M | 814.14%331.55M |
| Free cash flow | 20.52%-67.76M | -85.83%-140.08M | -77.78%-149.51M | -44.71%-325.71M | -38.30%-80.97M | -44.26%-85.26M | -31.18%-75.38M | -68.32%-84.1M | -22.24%-225.07M | -21.55%-58.54M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data